FHD-286

CAS No. 2671128-05-3

FHD-286 ( —— )

Catalog No. M28880 CAS No. 2671128-05-3

FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 335 Get Quote
10MG 520 Get Quote
25MG 840 Get Quote
50MG 1143 Get Quote
100MG 1521 Get Quote
500MG 3087 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    FHD-286
  • Note
    Research use only, not for human use.
  • Brief Description
    FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.
  • Description
    FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2671128-05-3
  • Formula Weight
    562.7
  • Molecular Formula
    C24H30N6O6S2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@H](C1)O[C@@H](C)CN1c1cccc(-c2csc(NC([C@H](COC)NC(c(cc3)cn3S(C)(=O)=O)=O)=O)n2)n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Qiao J, et al. Identification of a Novel Specific Cucurbitadienol Synthase Allele in Siraitia grosvenorii Correlates with High Catalytic Efficiency. Molecules. 2019 Feb 11;24(3).
molnova catalog
related products
  • UMB298

    UMB298 is a potent and selective CBP/P300 bromodomain inhibitor. UMB298 inhibits BRD4 with IC50 of 5193nM.

  • 2-methyl-2,3,4,5-tet...

    2-methyl-2,3-dihydro-1,5-benzothiazepin-4(5H)-one is ligand of CBP.

  • FHD-286

    FHD-286 is an inhibitor of BRM/BRG1 ATPase and can be used for studies on the treatment of BAF-related disorders such as acute myeloid leukemia.